Dr. Kremyanskaya on MANIFEST Trial With CPI-0610 in Myelofibrosis

(1:44)

CPI-0610 Demonstrates Activity in Patients With Myelofibrosis After Ruxolitinib Failure

(1:5)

BET Inhibitor pelabresib (CPI-0610) and ruxolitinib for myelofibrosis

(1:27)

Dr. Kremyanskaya on Responses With CPI-0610 in Patients With Myelofibrosis

(1:8)

Dr. Verstovsek on Examining CPI-0610 in Myelofibrosis

(1:48)

Evaluating CPI-0610 as Treatment of Patients With Myelofibrosis

(1:45)

Dr. Verstovsek on the MANIFEST Trial With CPI-0610 in Myelofibrosis

(1:45)

Pelabresib (CPI-0610): a novel BET inhibitor for MF

(2:8)

MANIFEST study of pelabresib (CPI-0610) in myelofibrosis

(3:6)

MANIFEST: pelabresib (CPI-0610) + ruxolitinib in advanced myelofibrosis patients

(3:49)

MANIFEST study: Should CPI-0610 be used as an add-on to ruxolitinib in patients with advanced MF?

(1:59)

MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in MF?

(3:38)

MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in myelofibrosis?

(3:57)

John Mascarenhas, MD, shares outcomes from the MANIFEST study examining CPI-0610 in myelofibrosis

(3:57)

How effective are JAK inhibitor combinations for patients with myelofibrosis?

(2:55)

What do the preliminary results of the MANIFEST trial say about CPI-0610 in treating MF?

(6:6)

Novel therapies for myelofibrosis

(2:41)

When should we give JAK inhibitors to patients with MF in the peri-transplant setting?

(4:40)

What are the promising new agents for patients with myelofibrosis?

(4:48)